Member Info for Kaeren

Exmex , I hadn't picked up on the linked in connections. I have wondered that myself as he must be highly sought after. Tried reading the paper published the
week before last and a few others , tbh none the wiser. Did think maybe transplant , but could be way off the mark.
Perhaps Poidster might understand his particular areas of research and could take more of an educated guess.

We need Troublesome to extol his virtues !
I would be banned.
Can't say I was enthused about the booth today Wilson , nor the laziness of reposting same picture. Some clients looking keen would have been preferable to a blank canvas. We have never been told about any lab in a box sales , but there it was again......
No hope of gleaning anything new from that !

*Their

Bowtie, I have no doubt Avacta will sore to great heights if trial results are good , early T/O would not surprise me. Today's rise was caused mainly by a twitter rumour that new news would be released on Saurday at a conference Avacta were participating in. The pump started , the Sp rose , those in the 'club ' made there 15 % and then Avacta effectively issued a speeding ticket - an RNS saying no new news on Saturday. Just the normal crap that goes on with AIM shares. Unfortunately it will be newbies caught , because anyone with even with minimal experience knows that any inf of material value must be released via RNS.
The above is my opinion only.

Exmex , I was looking at Clonit for that as I saw a while back they were developing. The idea of partnering stateside is more attractive , hope you are right and indeed that was one of the reasons for A.A 's trip , FYI P.O R&D was away from desk , known from mail response , at the same time. Too tenuous a link but a possible maybe. I thought perhaps he was in situ at ASHG with one of our distributors.

Some folks just get fed up with obvious disingenuous posters. Mr Rice has just ''accidentally ' posted on Angs how great the charts look on UKOG , so it would appear there is a reason for folks to get frustrated. All very childish as any news here will blow the doors off and from all I've read could be at any time. The dot could appear tomoz at 7.am and all those scaremongering efforts would have been futile.

A Novacyt employee was tasked with visiting key distributors to showcase new products and enhance the intraday working relationship between them and the company. He was not on a transatlantic jolly , on the lash, spending your money ! Your posting is deliberate to elicit a response. It is reflective of the sort of person you are. You lie constantly and have been caught out numerous times on this board. Do yourself a favour and find something else to do , then and only then will you find gainful emlpoy that pays you the salary increase you claim to have ( 50 %)
Well adjusted folks don't post such things , only those lacking in self belief . Another obvious lie by you , as you are on here day and night , which leaves little time to fulfil the normal obligations of a new job.
Shame the Novacyt staff member can't respond , he may have selected different words.
Disgraceful.
Personally pleased he went and hope it is representative of an expected increase in sales , we certainly need them .

It may , but very impressed with this BOD, afraid that although I've flirted with Copl I won't go in heavy as can't say I have the same comfort level. But hey ho I could be 100 % wrong and I accept that.
Gl

Not interested in next Boil , this is at the start of its journey to multi multi bags and we've been just been told Wed evening it's up for sale. Not rainbow chasing , exceptionally strong hold imo

Why should it mean either Doc ?

No . Never in the pipeline on the Novacyt website but mentioned in last Q & A.

Go to News Explorer
RNS
Miscellaneous
Share

CORRECTION: UK CTDA approval of Winterplex 3G
NOVACYT S.A.
Released 18:45:00 27 October 2022

RNS Number : 4115E
Novacyt S.A.
27 October 2022





This is a correction to the "UK Approval of genesig® SARS-CoV-2 Winterplex® 3G" announcement published at 7:00am on 26 October 2022 (RNS number 0989E) which incorrectly stated that Winterplex® 3G could use sputum and nasopharyngeal samples rather than anterior nasal samples (in addition to oropharyngeal samples)for the detection of influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 (COVID-19) (specifically the detection of ORF1ab, S and M genes targets).



All other information remains unchanged. The full corrected announcement is included below.





Novacyt S.A.

("Novacyt", the "Company" or the "Group")



Correction: Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene assay panel in the UK under CTDA legislation



A multiplex PCR test for the detection of winter viruses including SARS-CoV-2, influenza A and B, and RSV



Paris, France and Camberley, UK - 27 October 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's genesig® Real-Time PCR SARS-CoV-2 Winterplex® 3G assay panel (Winterplex® 3G) has been approved in the UK under the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA"), making it the Company's sixth PCR test to be added to the CTDA register of approved COVID-19 diagnostic products.



Winterplex® 3G is a high throughput multiplex screening assay (with 96 reactions per kit) for the detection of influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 (COVID-19) (specifically the detection of ORF1ab, S and M genes targets) from oropharyngeal and anterior nasal samples.



This approval comes in advance of the winter virus season in the northern hemisphere and means the Company can now sell Winterplex® 3G in the UK. Winterplex® 3G allows healthcare systems to differentiate between common respiratory infections which present with similar symptoms. As the prevalence of winter viruses increases, Novacyt continues to monitor all strains of influenza A, influenza B, RSV and SARS-CoV-2 through its bioinformatics surveillance programme.



David Allmond, Group CEO of Novacyt, commented:

"We are pleased Winterplex® 3G has been approved under the UK's CTDA legislation. This product is a combined assay which offers the benefit of testing for multiple seasonal viruses at the same time, saving time and requiring only one patient sample. We believe this is important as the diagnostics market moves towards favouring respiratory panels over COVID-19-specific testing due to concerns about the dual rise in COVID-19 and influenza cases this winter. This latest approval ensures we are well-positioned wi

Good Novacyt have issued a correction to their RNS re CTDA and Winterplex. Ridiculous it was necessary and spotted by holders and not internal proof readers

Yeah , anyone planning a fireworks display , then you know where to stick the rocket launcher.
We are stuck on the Katherine wheel and we don't even have sparklers to pass the time.

They need to have a word with themselves then , no bs needed here .

??? No Opinion , just sharing
https://twitter.com/FionaThompson64/status/1584864323419377665?s=20&t=eddilrxGzzZRpLmR42aN_A

For those lacking the mental acuity to comprehend that Winterplex is not a covid test .

https://twitter.com/NovacytGroup/status/1585543469744984064?s=20&t=7tr9IL1ZcPojzyvg0k-2cw
Quite remarkable the tenacity in the face of clarity , the constant insistance the latest CTDA authorisation is for a covid test and covid is over. It is a multi respiratory test that will be in demand this winter , obviously we do not know how much our test will be utilised. However at least this time we are in the running and CTDA have cleared the test in time to enable our sales guys to hit the road with a product for winter 2022.

I have listened to many presentations over the years and that was in the top few ever.
Crystal clear this will multi multi bag, what day , what month is the question. Imo.

Well Lat not worthless , a prerequisite to getting a contract.
Tbh haven't done research on how many similar tests approved and what they run on. Re a contract , will these be ordered at national level or will it be hard sell into diff NHS hubs, that Novacyct claimed was beneficial to them ( not evidenced )

Thanks KT , no evaluation under 7 although we know it is and none under number nine .